Lv11
80 积分 2026-03-24 加入
Firmonertinib plus Radiotherapy vs. Concurrent Chemoradiotherapy followed by Firmonertinib Consolidation in Unresectable Stage III EGFR-mutant NSCLC: A Randomized Phase 2 Trial
1小时前
待确认
Firmonertinib 160mg in EGFR-Mutated NSCLC with Brain Metastases After EGFR-TKI Resistance (iFORCE): Clinical Outcomes and Mechanistic Insights
1小时前
已关闭
FAK co-inhibition in KRASG12C-mutated non-small-cell lung cancer
1个月前
已关闭
Incidence of Radiation Pneumonitis Following EGFR-TKI Combined With Thoracic Radiotherapy in Unresectable Stage III or IV Non-Small-Cell Lung Cancer: A Systematic Review and Meta-analysis
1个月前
已关闭
High-dose furmonertinib plus bevacizumab and intrathecal pemetrexed for EGFR-RAD51 fusion-positive lung adenocarcinoma with leptomeningeal metastasis: Insights from serial CSF ctDNA monitoring
1个月前
已完结
Efficacy of Vebreltinib in Advanced Lung Adenocarcinoma With c-MET Amplification
4个月前
已关闭
Structure-based classification for differential tyrosine kinase inhibitors efficacy of EGFR exon 19 deletions in non-small cell lung cancer
5个月前
已关闭
Development, validation and clinical application of a LC-MS/MS method for simultaneous determination of third-generation EGFR-TKIs and metabolites in patients with NSCLC
6个月前
已关闭
Critical Appraisal of PD-L1 Expression as a Predictive Biomarker for EGFR-TKI Efficacy in Lung Squamous Cell Carcinoma
6个月前
已关闭
Making Progress Along the Challenging Road of Drug Development for Patients With EGFR Exon 20 Insertion–Positive Non–Small Cell Lung Cancer
6个月前
已完结
皖公网安备34019202002308
